Merck’s Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Mer­ck said Fri­day morn­ing that its HIF-2α in­hibitor Welireg met the co-pri­ma­ry end­point of pro­gres­sion-free sur­vival in a Phase III tri­al for pa­tients with ad­vanced forms of re­nal cell car­ci­no­ma, but it did not meet the oth­er co-pri­ma­ry end­point of over­all sur­vival.

The topline da­ta come from a head-to-head Phase III tri­al with everolimus, al­so known as No­var­tis’ Afin­i­tor, test­ing Welireg in pre-treat­ed pa­tients with ad­vanced forms of re­nal cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.